A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement.
Bortezomib, a proteasome inhibitor used in the treatment of multiple myeloma, is known to induce an axonal, dose-dependent neuropathy clinically characterized by pain, paresthesias, burning dysesthesias and numbness. In this study, we describe a patient treated with high-dose bortezomib whose main clinical feature was severe sensory ataxia. Electrodiagnostic studies showed, other than axonal changes, myelin involvement.
Filosto
Massimiliano
M
Clinical Neurology, Section for Neuromuscular Diseases and Neuropathies, University Hospital "Spedali Civili", Brescia, Italy. filosto@med.unibs.it
Rossi
Giuseppe
G
Pelizzari
Anna Maria
AM
Buzio
Serena
S
Tentorio
Marta
M
Broglio
Laura
L
Mancuso
Michelangelo
M
Rinaldi
Marianna
M
Scarpelli
Mauro
M
Padovani
Alessandro
A
D000368:Aged; D001259:Ataxia / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D009186:Myelin Sheath / Q000187:drug effects / Q000502:physiology*; D009431:Neural Conduction / Q000187:drug effects / Q000502:physiology; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology
D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib